GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Yizhong Pharmaceutical Co Ltd (SHSE:688091) » Definitions » Capex-to-Revenue

Shanghai Yizhong Pharmaceutical Co (SHSE:688091) Capex-to-Revenue : 0.01 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai Yizhong Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Shanghai Yizhong Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-0.43 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥71.03 Mil.

Hence, Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2025 was 0.01.


Shanghai Yizhong Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Yizhong Pharmaceutical Co Capex-to-Revenue Chart

Shanghai Yizhong Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial - 0.77 0.15 0.02 0.46

Shanghai Yizhong Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.19 0.75 6.98 0.01

Competitive Comparison of Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue falls into.


;
;

Shanghai Yizhong Pharmaceutical Co Capex-to-Revenue Calculation

Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-80.036) / 173.533
=0.46

Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.427) / 71.032
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Yizhong Pharmaceutical Co  (SHSE:688091) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Shanghai Yizhong Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Yizhong Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Yizhong Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
79 Renqi Road, Fengxian District, Shanghai, CHN, 201403
Shanghai Yizhong Pharmaceutical Co Ltd is a pharmaceutical enterprise integrating research and development, production and sales. It is committed towards the development of new dosage forms of anti-tumor drugs and related products.
Executives
Liu Gang Core technical personnel
Qiu Yi Core technical personnel
Du Xue Hang Director
Sun Jing Directors, senior managers, core technical personn
Zhou Jin Song Directors, senior managers, core technical personn
Li Duan Directors, senior managers, core technical personn

Shanghai Yizhong Pharmaceutical Co Headlines

No Headlines